Clinical Trial Update: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 [Phase 4]

View source ↗

Summary

A 12-month, open-label, multicenter Phase 4 trial evaluating health outcomes of fingolimod (FTY720) in relapsing-remitting multiple sclerosis; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED | Results posted: 2016-06-07